The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1^st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real- life data report 2013–2018

1Cancer in Slovenia 2018. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2021. Cancer in Slovenia 2018 Ljubljana Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry 2021Search in Google Scholar

2Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516. doi:10.1093/annonc/mds236 Schmoll HJ Van Cutsem E Stein A Valentini V Glimelius B Haustermans K et al ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 2012 23 2479 516 doi10.1093/annonc/mds236Open DOISearch in Google Scholar

3van Cutsem E, Cervantes A, Adam R, Sobrero S, J. van Krieken JH, Aderka D, et al ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-422. doi:10.1093/annonc/mdw235 van Cutsem E Cervantes A Adam R Sobrero S J. van Krieken JH Aderka D et al ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Ann Oncol 2016 27 1386 422 doi10.1093/annonc/mdw235Open DOISearch in Google Scholar

4National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. V.1.2022. [cited 2022 Aug 25]. Avaible at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdf National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. V.1.2022 [cited 2022 Aug 25]. Avaible at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdfSearch in Google Scholar

5National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. V.1.2022. [cited 2022 Aug 25]. Avaible at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdf National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. V.1.2022 [cited 2022 Aug 25]. Avaible at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdfSearch in Google Scholar

6Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et a. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37. doi: 10.1200/JCO.2004.05.113. Epub 2003 Dec 2. PMID: 14657227 Tournigand C André T Achille E Lledo G Flesh M Mery-Mignard D et a FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 2004 22 229 37 doi 10.1200/JCO.2004.05.113. Epub 2003 Dec 2. PMID: 14657227Open DOISearch in Google Scholar

7Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-14. doi: 10.1200/JCO.2004.11.037. PMID: 15051767 Grothey A Sargent D Goldberg RM Schmoll HJ Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 2004 22 1209 14 doi 10.1200/JCO.2004.11.037. PMID: 15051767Open DOISearch in Google Scholar

8Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42. doi: 10.1056/NEJMoa032691 Hurwitz H Fehrenbacher L Novotny W Cartwright T Hainsworth J Heim W et al Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 2004 350 2335 42 doi 10.1056/NEJMoa032691Open DOISearch in Google Scholar

9Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9. doi: 10.1200/JCO.2007.14.9930. Erratum in J Clin Oncol 2008; 26: 3110. Erratum in: J Clin Oncol 2009; 27: 653. PMID: 18421054 Saltz LB Clarke S Díaz-Rubio E Scheithauer W Figer A Wong R et al Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 2008 26 2013 9 doi 10.1200/JCO.2007.14.9930. Erratum in J Clin Oncol 2008; 26: 3110. Erratum in: J Clin Oncol 2009; 27: 653. PMID: 18421054Open DOISearch in Google Scholar

10Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17. doi: 10.1056/NEJMoa0805019 Van Cutsem E Köhne CH Hitre E Zaluski J Chang Chien CR Makhson A et al Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 2009 360 1408 17 doi 10.1056/NEJMoa0805019Open DOISearch in Google Scholar

11Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71. doi: 10.1200/JCO.2008.20.8397 Bokemeyer C Bondarenko I Makhson A Hartmann JT Aparicio J de Braud F et al Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 2009 27 663 71 doi 10.1200/JCO.2008.20.8397Open DOISearch in Google Scholar

12Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-46. doi: 10.1093/annonc/mdq632 Bokemeyer C Bondarenko I Hartmann JT de Braud F Schuch G Zubel A et al Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 2011 22 1535 46 doi 10.1093/annonc/mdq632Open DOISearch in Google Scholar

13Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-9. doi: 10.1093/annonc/mdi246 Folprecht G Grothey A Alberts S Raab HR Köhne CH Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates Ann Oncol 2005 16 1311 9 doi 10.1093/annonc/mdi246Open DOISearch in Google Scholar

14Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-57; discussion 657-8. doi: 10.1097/01.sla.0000141198.92114.f6 Adam R Delvart V Pascal G Valeanu A Castaing D Azoulay D et al Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann Surg 2004 240 644 57 discussion 657-8 doi 10.1097/01.sla.0000141198.92114.f6Open DOISearch in Google Scholar

15Bellio H, Fumet JD, Ghiringhelli F. Targeting BRAF and RAS in colorectal cancer. Cancers 2021; 13: 2201. doi: 10.3390/cancers13092201 Bellio H Fumet JD Ghiringhelli F Targeting BRAF and RAS in colorectal cancer Cancers 2021 13 2201 doi 10.3390/cancers13092201Open DOISearch in Google Scholar

16Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol 2016; 7: 687-704. doi: 10.21037/jgo.2016.06.12 Gong J Cho M Fakih M RAS and BRAF in metastatic colorectal cancer management J Gastrointest Oncol 2016 7 687 704 doi 10.21037/jgo.2016.06.12Open DOISearch in Google Scholar

17Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-7. doi: 10.1038/327293a0. PMID: 3587348 Bos JL Fearon ER Hamilton SR Verlaan-de Vries M van Boom JH van der Eb AJ et al Prevalence of ras gene mutations in human colorectal cancers Nature 1987 327 293 7 doi 10.1038/327293a0. PMID: 3587348Open DOISearch in Google Scholar

18Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32. doi: 10.1056/NEJM198809013190901 Vogelstein B Fearon ER Hamilton SR Kern SE Preisinger AC Leppert M et al Genetic alterations during colorectal-tumor development N Engl J Med 1988 319 525 32 doi 10.1056/NEJM198809013190901Open DOISearch in Google Scholar

19Zhu D, Keohavong P, Finkelstein SD, Swalsky P, Bakker A, Weissfeld J, et al. K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res 1997; 57: 2485-92. PMID: 9192830 Zhu D Keohavong P Finkelstein SD Swalsky P Bakker A Weissfeld J et al K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients Cancer Res 1997 57 2485 92 PMID: 9192830Search in Google Scholar

20Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60. doi: 10.1056/NEJMra0804588 Markowitz SD Bertagnolli MM Molecular basis of colorectal cancer N Engl J Med 2009 361 2449 60 doi 10.1056/NEJMra0804588Open DOISearch in Google Scholar

21Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 2008; 14: 3651-6. doi: 10.1158/1078-0432.CCR-08-0333 Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway Clin Cancer Res 2008 14 3651 6 doi 10.1158/1078-0432.CCR-08-0333Open DOISearch in Google Scholar

22Ličar A, Cerkovnik P, Novaković S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 2011; 28: 1048-53. doi: 10.1007/s12032-010-9631-z Ličar A Cerkovnik P Novaković S Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer Med Oncol 2011 28 1048 53 doi 10.1007/s12032-010-9631-zOpen DOISearch in Google Scholar

23De Roock W, Jonker DJ, De Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with outcome with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-20. doi: 10.1001/jama.2010.1535 De Roock W Jonker DJ De Nicolantonio F Sartore-Bianchi A Tu D Siena S et al Association of KRAS p.G13D mutation with outcome in patients with outcome with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 2010 304 1812 20 doi 10.1001/jama.2010.1535Open DOISearch in Google Scholar

24De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62. doi: 10.1016/S1470-2045(10)70130-3 De Roock W Claes B Bernasconi D De Schutter J Biesmans B Fountzilas G et al Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 2010 11 753 62 doi 10.1016/S1470-2045(10)70130-3Open DOISearch in Google Scholar

25Artale S, Sartore- Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-9. doi:10.1200/JCO.2008.18.7266 Artale S Sartore- Bianchi A Veronese SM Gambi V Sarnataro CS Gambacorta M et al Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer J Clin Oncol 2008 26 4217 9 doi10.1200/JCO.2008.18.7266Open DOISearch in Google Scholar

26Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta Met al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-9. doi: 10.1200/JCO.2008.18.7286 Artale S Sartore-Bianchi A Veronese SM Gambi V Sarnataro CS Gambacorta Met al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer J Clin Oncol 2008 26 4217 9 doi 10.1200/JCO.2008.18.7286Open DOISearch in Google Scholar

27Lamprechts D, De Roock W, Prenen H, Schutter JD, Jacobs B, Biesmans B, et al. The role of KRAS, BRAF, NRAS and PIK3CA mutations as a markers of resistence of cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol 2009; 27: 9020. doi: 10.1158/1078-0432.CCR-08-2961 Lamprechts D De Roock W Prenen H Schutter JD Jacobs B Biesmans B et al The role of KRAS, BRAF, NRAS and PIK3CA mutations as a markers of resistence of cetuximab in chemorefractory metastatic colorectal cancer J Clin Oncol 2009 27 9020 doi 10.1158/1078-0432.CCR-08-2961Open DOISearch in Google Scholar

28Tejpar S, De Roock W, Claes B, Fountzilas G. PIKI3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium. 8th Annual Meeting of the Japanese-Society-of-Medical-Oncology Ann Oncol 2010; 21(Suppl 9): 6. Tejpar S De Roock W Claes B Fountzilas G PIKI3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium. 8th Annual Meeting of the Japanese-Society-of-Medical-Oncology Ann Oncol 2010 21Suppl 9 6Search in Google Scholar

29Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab + irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-21. doi: 10.18632/oncotarget.13697 Loupakis F Ruzzo A Cremolini C Vincenzi B Salvatore L Santini D et al KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab + irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 2009 101 715 21 doi 10.18632/oncotarget.13697Open DOISearch in Google Scholar

30Peters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R et al. Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): assessment as prognostic and predictive bio-markers of response to panitumumab (pmab). [abstract]. J Clin Oncol 2012; 30(Suppl 4): abstr 383. Peters M Douillard JY Van Cutsem E Siena S Zhang K Williams R et al Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): assessment as prognostic and predictive bio-markers of response to panitumumab (pmab). [abstract] J Clin Oncol 2012 30(Suppl 4): abstr 383Search in Google Scholar

31Tejpar S, Celic I, Schlichting M, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-7. doi: 10.1200/JCO.2012.42.2592 Tejpar S Celic I Schlichting M Bokemeyer C Van Cutsem E Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 2012 30 3570 7 doi 10.1200/JCO.2012.42.2592Open DOISearch in Google Scholar

32Fujiyoshi K, Yamamoto G, Takahashi A, Arai Y, Yamada M, Kakuta M, et al. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep 2017; 37: 785-92. doi: 10.3892/or.2016.5323 Fujiyoshi K Yamamoto G Takahashi A Arai Y Yamada M Kakuta M et al High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases Oncol Rep 2017 37 785 92 doi 10.3892/or.2016.5323Open DOISearch in Google Scholar

33Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94: 76-81. doi: 10.1016/j. radonc.2009.10.001 Gaedcke J Grade M Jung K Schirmer M Jo P Obermeyer C et al KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy Radiother Oncol 2010 94 76 81 doi 10.1016/j.radonc.2009.10.001Open DOISearch in Google Scholar

34Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2015; 96: 156-66. doi: 10.1016/j.critrevonc.2015.05.016 Pietrantonio F Cremolini C Petrelli F Di Bartolomeo M Loupakis F Maggi C et al First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis Crit Rev Oncol Hematol 2015 96 156 66 doi 10.1016/j.critrevonc.2015.05.016Open DOISearch in Google Scholar

35Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26: 13-21. doi: 10.1093/annonc/mdu378 Sorich MJ Wiese MD Rowland A Kichenadasse G McKinnon RA Karapetis CS et al Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials Ann Oncol 2015 26 13 21 doi 10.1093/annonc/mdu378Open DOISearch in Google Scholar

36Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014; 53: 852-64. doi: 10.3109/0284186X.2014.895036 Therkildsen C Bergmann TK Henrichsen-Schnack T Ladelund S Nilbert M The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis Acta Oncol 2014 53 852 64 doi 10.3109/0284186X.2014.895036Open DOISearch in Google Scholar

37Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65. doi: 10.1056/NEJMoa0804385 Karapetis CS Khambata-Ford S Jonker DJ O’Callaghan CJ Tu D Tebbutt NC et al K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 2008 359 1757 65 doi 10.1056/NEJMoa0804385Open DOISearch in Google Scholar

38Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7. PMID: 11097226 Samowitz WS Curtin K Schaffer D Robertson M Leppert M Slattery ML Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study Cancer Epidemiol Biomarkers Prev 2000 9 1193 7 PMID: 11097226Search in Google Scholar

39Van Cutsem E Köhne CH, La´ng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9. doi: 10.1200/JCO.2010.33.5091 Van Cutsem E Köhne CH La´ng I Folprecht G Nowacki MP Cascinu S et al Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 2011 29 2011 9 doi 10.1200/JCO.2010.33.5091Open DOISearch in Google Scholar

40Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-46. doi: 10.1093/annonc/mdq632 Bokemeyer C Bondarenko I Hartmann JT de Braud F Schuch G Zubel A et al Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 2011 22 1535 46 doi 10.1093/annonc/mdq632Open DOISearch in Google Scholar

41Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34. doi: 10.1056/NEJMoa1305275 Douillard JY Oliner KS Siena S Tabernero J Burkes R Barugel M et al Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 2013 369 1023 34 doi 10.1056/NEJMoa1305275Open DOISearch in Google Scholar

42Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-15. doi: 10.1016/S1470-2045(15)00122-9. Cremolini C Loupakis F Antoniotti C Lupi C Sensi E Lonardi S et al FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study Lancet Oncol 2015 16 1306 15 doi 10.1016/S1470-2045(15)00122-9Open DOISearch in Google Scholar

43Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-9. doi: 10.3978/j.issn.2078-6891.2015.077 Tol J Nagtegaal ID Punt CJA BRAF mutation in metastatic colorectal cancer N Engl J Med 2009 361 98 9 doi 10.3978/j.issn.2078-6891.2015.077Open DOISearch in Google Scholar

44Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associatedwith the BRAF V600E mutation in microsatellite-stable colon cancer. Caner Res 2005; 65: 6063-9. doi: 10.1158/0008-5472.CAN-05-0404 Samowitz WS Sweeney C Herrick J Albertsen H Levin TR Murtaugh MA et al Poor survival associatedwith the BRAF V600E mutation in microsatellite-stable colon cancer Caner Res 2005 65 6063 9 doi 10.1158/0008-5472.CAN-05-0404Open DOISearch in Google Scholar

45Rebersek M, Mesti T, Boc M, Ocvirk J. Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients. Radiol Oncol 2019; 53: 85-95. doi: 10.2478/raon-2019-0013 Rebersek M Mesti T Boc M Ocvirk J Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients Radiol Oncol 2019 53 85 95 doi 10.2478/raon-2019-0013Open DOISearch in Google Scholar

46Rebersek M, Boc M, Škerl P, Benedik J, Hlebanja Z, Volk N, et al. Efficacy of First- line systemic treatment in correlation with BRAF V600E and different KRAS mutations colorectal cancer - a single institution retrospective analysis. Radiol Oncol 2011; 45: 285-91. doi: 10.2478/v10019-011-0039-y Rebersek M Boc M Škerl P Benedik J Hlebanja Z Volk N et al Efficacy of First- line systemic treatment in correlation with BRAF V600E and different KRAS mutations colorectal cancer - a single institution retrospective analysis Radiol Oncol 2011 45 285 91 doi 10.2478/v10019-011-0039-yOpen DOISearch in Google Scholar